178 related articles for article (PubMed ID: 24551032)
21. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.
Park JJ; Stewart A; Irvine M; Pedersen B; Ming Z; Carlino MS; Diefenbach RJ; Rizos H
Cancer Gene Ther; 2022 Oct; 29(10):1384-1393. PubMed ID: 35352024
[TBL] [Abstract][Full Text] [Related]
22. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.
Marchion DC; Bicaku E; Xiong Y; Bou Zgheib N; Al Sawah E; Stickles XB; Judson PL; Lopez AS; Cubitt CL; Gonzalez-Bosquet J; Wenham RM; Apte SM; Berglund A; Lancaster JM
Oncol Rep; 2013 May; 29(5):2011-8. PubMed ID: 23467907
[TBL] [Abstract][Full Text] [Related]
23. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
[TBL] [Abstract][Full Text] [Related]
24. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
25. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
Jagadeeswaran R; Ma PC; Seiwert TY; Jagadeeswaran S; Zumba O; Nallasura V; Ahmed S; Filiberti R; Paganuzzi M; Puntoni R; Kratzke RA; Gordon GJ; Sugarbaker DJ; Bueno R; Janamanchi V; Bindokas VP; Kindler HL; Salgia R
Cancer Res; 2006 Jan; 66(1):352-61. PubMed ID: 16397249
[TBL] [Abstract][Full Text] [Related]
26. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
Wu X; Li J; Zhu M; Fletcher JA; Hodi FS
Mol Cancer Ther; 2012 Sep; 11(9):1905-14. PubMed ID: 22653968
[TBL] [Abstract][Full Text] [Related]
27. Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.
Cheng H; Terai M; Kageyama K; Ozaki S; McCue PA; Sato T; Aplin AE
Cancer Res; 2015 Jul; 75(13):2737-48. PubMed ID: 25952648
[TBL] [Abstract][Full Text] [Related]
28. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.
Dai Y; Siemann DW
BMC Cancer; 2012 May; 12():198. PubMed ID: 22639908
[TBL] [Abstract][Full Text] [Related]
29. Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.
Pei J; Chu T; Shao M; Teng J; Sha H; Gu A; Li R; Qian J; Mao W; Li Y; Han B
Yonsei Med J; 2017 May; 58(3):581-591. PubMed ID: 28332364
[TBL] [Abstract][Full Text] [Related]
30. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
31. Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells.
Zhang R; Shi H; Chen Z; Wu Q; Ren F; Huang H
J Exp Clin Cancer Res; 2011 Sep; 30(1):83. PubMed ID: 21923915
[TBL] [Abstract][Full Text] [Related]
32. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.
Zillhardt M; Christensen JG; Lengyel E
Neoplasia; 2010 Jan; 12(1):1-10. PubMed ID: 20072648
[TBL] [Abstract][Full Text] [Related]
33. Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling.
Liu H; Lei C; Long K; Yang X; Zhu Z; Zhang L; Liu J
Oncol Rep; 2015 Jul; 34(1):295-301. PubMed ID: 25955651
[TBL] [Abstract][Full Text] [Related]
34. Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion.
Cao HH; Cheng CY; Su T; Fu XQ; Guo H; Li T; Tse AK; Kwan HY; Yu H; Yu ZL
Mol Cancer; 2015 May; 14():103. PubMed ID: 25971889
[TBL] [Abstract][Full Text] [Related]
35. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
[TBL] [Abstract][Full Text] [Related]
36. Natural withanolide withaferin A induces apoptosis in uveal melanoma cells by suppression of Akt and c-MET activation.
Samadi AK; Cohen SM; Mukerji R; Chaguturu V; Zhang X; Timmermann BN; Cohen MS; Person EA
Tumour Biol; 2012 Aug; 33(4):1179-89. PubMed ID: 22477711
[TBL] [Abstract][Full Text] [Related]
37. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
[TBL] [Abstract][Full Text] [Related]
38. Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1.
Ozen E; Gozukizil A; Erdal E; Uren A; Bottaro DP; Atabey N
PLoS One; 2012; 7(8):e42717. PubMed ID: 22912725
[TBL] [Abstract][Full Text] [Related]
39. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway.
Tan S; Li R; Ding K; Lobie PE; Zhu T
FEBS Lett; 2011 Jul; 585(14):2229-34. PubMed ID: 21658389
[TBL] [Abstract][Full Text] [Related]
40. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.
Dai Y; Siemann DW
Mol Cancer Ther; 2010 Jun; 9(6):1554-61. PubMed ID: 20515943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]